About us

 

 

An Overview  of Medical Genetics Lab of Dr Zamani

Medical Genetics Laboratory of Dr Zamani as a well-known private center provides a wide variety of medical genetics tests and services. The director, Dr Mehdi Zamani, has PhD in Medical genetics and post-doctorate in genetic diseases and risk factor analysis both from Leuven University, Belgium. Dr. Zamani is a faculty member of Tehran University of Medical Sciences. He is the founder, as well as, the current director of Medical Genetics Division of Children’s Clinical Center Hospital and Medical Genetics Laboratory of Dr. Zamani

Dr. Zamani is a member of  the following societies:

-New york  Academy of Science

-European Association of Diabetes Study (EADS)

-The exclusive representative of  EU’s Thematic network for CF disease in Iran.

Having been graduated from Leuven university in 1997, Dr Zamani has since been actively involved in the molecular diagnosis and genetic counseling of the genetic diseases both at Medical Genetics Division of Children’s Clinical Center hospital and his private lab.

A list of the international published papers by Dr Zamani is shown:

Author of publications in international Journals

 

  1. Zamani Ghabanbasani M, Buyse I, Legius E, Decorte R, Marynen P, Bouillon R and Cassiman JJ (1994): Possible association of CD3 and CD4 Polymorphisms with IDDM. Exp. Immunology 97:517-521
  2. Zamani Ghabanbasani M, Spaepen M, Buyse I, Marynen P, Bex M, Bouillon R and Cassiman JJ (1994): Improved risk assessment for IDDM by analysis of amino acids in HLA- DQ and DRB1 loci. Eur J Human Genetics 2:177-184
  3. Zamani Ghabanbasani M, De Hert M, Spaepen M, Hermans M, Marynen P, Cassiman JJ and Peuskens J (1994): Study of the possible association of HLA class II, CD4 and CD3 polymorphisms with schizophrenia. Am J Medical Genetics. 54:372-377
  4. Buyse I, Sandkuyl LA, Zamani Ghabanbasani M, Gu XX, Bouillon R, BeX M, Dooms L, Emonds MP, Duhamel M, Marynen P and Cassiman JJ (1994): Association of particular HLA class II alleles, haplotypes, and genotypes with susceptibility to insulin dependent diabetes mellitus in the Belgian population. Diabetologia 37:808-817
  5. Decorte R, Buyse I, Zamani M, Gu XX, Spaepen M, Marynen P, De Canck l, Emonds M and Cassiman JJ (1994): Distribution of HLA Class II genes in a Caucasian population as determined by PCR and reversed-dot-blot typing. Forensic Haemogenet. 5:490-492
  6. Vandevyver C, Buyse I, Philippaerts L, Zamani Ghabanbasani M, Medaer R, Carton H, Cassiman JJ and Raus J (1994): HLA and T-cell receptor polymorphisms in Belgian multiple sclerosis patients. J of Neuroimmonology 52:25-32
  7. Zamani Ghabanbasani M , Spaepen M, Buyse I, Legius E, Decorte R, Bex M, Marynen P, Bouillon R and Cassiman JJ (1995): Increased and decreased relative risk for Non- insulin-dependent diabetes mellitus conferred by HLA class II and by CD4 alleles. Clinical Genetics 47:225-230.
  8. Zamani Ghabanbasani M, Gu XX, Spaepen M, Vandevyver C, Raus J, Marynen P, Carton H and Cassiman JJ (1995): Importance of HLA-DRB1 and DQA1 genes and of the amino acid polymorphisms in the functional domain of DRB1 chain in Multiple Sclerosis. J of Neuroimmonology 59:77-82.
  9. Zamani M, Pociot F, Raeymaekers P, Nerup J and Cassiman JJ (1996): Linkage of type I diabetes to 15q26 (IDDM3) in Danish population. Human Genet 98:491-496
  10. Zamani M, Pociot F, Spaepen M, Raeymaekers P, Nerup J and Cassiman JJ (1996): Linkage and association of the HLA gene complex with IDDM in Danish families: Strong linkage between DRb1Lys71+ and IDDM. J Medical Genetics 33:899-905
  11. Zamani M and Cassiman JJ. (1998) : Reevaluation of the importance of polymorphic HLA class II alleles and amino acids in the susceptibility of individuals to type I Diabetes in different populations. Am J Medical Genetics 76:183-194
  12. Kiristiansen OP, Zamani M, Johannesen J, Mandrup-Poulsen T, Cassiman JJ, Nerup J, Pociot F, DIEGG and DSGD(1998): Linkage between a CD4 gene polymorphism and IDDM in Danish IDDM patients. Diabetes 47:281-283
  13. Pandey J, Zamani M and Cassiman JJ. (1999) : Epistatic effects of genes encoding tumor necrosis factor a, immunoglobulin allotypes, and HLA antigens on susceptibility to non-insulin dependent (type 2) diabetes. Immunogenetics 49:860-864
  14. Zamani M , Spaepen M, Bex M, , Bouillon R and Cassiman JJ (2000): Primary role of the  HLA class II DRB1*0301 allele in Graves’ Disease. Am J Medical Genetics: 95:432-437
  15. Zamani M , Huang C, Spaepen M and Cassiman JJ and (2001): Linkage and association of the HLA class II genes with vitiligo in Dutch families. British j of Dermatology 144:90-94
  16. Rahmani S.A., Mohadess S.M., Aghazadeh A, Jahani M, Izadyar M, Zamani M and Mehdipour P. (2006): Investigation of TEL/AML1 and BCR/ABL fusion genes in patients affected by acute lymphoblastic leukaemia using interphase in situ hybridization. Journal of Sciences, .I.R. of Iran 17:17-25
  17. Behjati F, Atri m, Najmabadi H, Nouri K, Zamani M and Mehdipour P (2006): Prognostic value of chromosome 1 and 8 copy number in invasive Ductal breast carcinoma among Iranian women: An interphase FISH analysis. Pathology Oncology Research 11:157-163
  18. Alibahksh R. and Zamani M. (2006) Mutation analysis of CFTR gene in 70 Iranian pationts by ARMS-PCR. Iranian J Allergy, Asthma and Immunology  5:3-8
  19. Korzebor, M. Zamani, K. Nouri and M. H. Modarressi. (2007) Statistical analysis of six STR loci located in MHC region in Iranian population for preimplantation genetic diagnosis. International Journal of Immunogenetics 34, 441–443
  20. Reza Alibakhshi, Roya Kianishirazi, Jean-Jacques Cassiman, Mahdi Zamania, , and Harry Cuppens (2008) Analysis of the CFTR gene in Iranian cystic fibrosis patients: Identification of eight novel mutations Journal of Cystic Fibrosis7, 102-109
  21. Majid Shahbazi , Hamid Ebadi, Davood Fathi,  Danial Roshandel, Mana Mahamadhoseeni,  Azam Rashidbaghan, Narges Mahammadi, Mahammad Reza Mahammadi and Mahdi Zamani. (2009) CCR5-Delta32 Allele is Associated with the Risk of Developing Multiple Sclerosis in the Iranian Population. Cell Mol Neurobiol  29:1205–1209
  22. Shahbazi M, Ebadi H, Fathi D, Roshandel D, Mohamadhosseni M, Tahmasebi A, Shahbazi S, Zamani M, Rashidbaghan A.(2010) HLA-DRB1*1501 intensifies the impact of IL-6 promoter polymorphism on the susceptibility to multiple sclerosis in an Iranian population. Mult Scler. 16:1173-7.
  23. Zamani, M. A. Tabatabaiefar, S. Mosayyebi, A. Mashaghi and P. Mansouri (2010) Possible Association of the CD4 Gene polymorphism With Vitiligo Disorder in the Iranian Population. Clin Exp Dermatol. 2010 Jul;35(5):521-4
  24. Shahbazi M, Roshandel D, Ebadi H, Fathi D, Zamani M, Boghaee M, Mohammadhoseeeni M, Rshaidbaghan A, Bakhshandeh A, Shahbazi S.(1010) High frequency of the IL-2 -330 T/HLA-DRB1*1501 haplotype in patients with multiple sclerosis. Clin Immunol. 137:134-8.
  25. Zamani, M. Mehri, A. Kollaee, P. Yenki, M. Ghaffarpor, M.H. Harirchian, M. Shahbazi (2011) Pharmacogenetic Study on the Effect of Rivastigmine on PS2 and APOE Genes in Iranian Alzheimer Patients. Dement Geriatr Cogn Disord Extra 1:180–189.
  26. M Zamani, V. Salahshour, A.Kollaee, G. R. Zamani, M. Sheidai, M. Mohammadi, and M. Ghaffarpor (2011). Intragenic DNA Polymorphism Analysis of DMD/BMD Dystrophy Gene for Carrier and Prenatal Diagnosis in 60 Iranian Healthy Individuals. International Journal of Neuroscience. 121: 551–556
  27. Kollaee, M. Ghaffarpor, H. Pourmahmoudian, M. Shahbazi and M. Zamani (2011) Investigation of CD24 and Its Expression in Iranian Relapsing-Remitting Multiple Sclerosis. International Journal of Neuroscience.121(12):684-90.
  28. Kollaee A, Ghaffarpor M, Ghlichnia HA, Ghaffari SH, Zamani M. The influence of the HLA-DRB1 and HLA-DQB1 allele heterogeneity on disease risk and severity in Iranian multiple sclerosis patients (2012). International Journal of Immunogenetics. In press
  29. Sayad A, Akbari MT, Pajouhi M, Mostafavi F, Zamani M. The influence of the HLA-DRB, HLA-DQB and polymorphic positions of the HLA-DRβ1 and HLA-DQβ1 molecules on risk of Iranian type 1 diabetes mellitus patients. International Journal of Immunogenetics. In press

Contact us: Tel:(+98 21)88003811-12